Document is current
Any future updates will be listed below
-
Authors
Cella, David
de la Loge, Christine
Fofana, Fatoumata
Guo, Shien
Ellis, Alicia
Fleurinck, Carmen
Massow, Ute
Dougados, Maxime
Navarro-Compán, Victoria
Walsh, Jessica A.
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 26 July 2023
Accepted: 24 July 2024
First Online: 12 August 2024
Declarations
:
: All research was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. All participants provided written informed consent in accordance with local requirements. Ethical approvals for BE MOBILE 1 and BE MOBILE 2 were obtained from the relevant institutional review boards or independent ethics committees at participating sites. Ethical approval for the qualitative study was obtained from Advarra Independent Review Board.
: Not applicable.
: DC is the president of FACIT.org. CdlL received consulting fees from UCB for this work. FF is an employee of Evidera PPD, a consultancy that received research funding from UCB Pharma to conduct this analysis. SG is an employee of Evidera PPD, a consultancy that received research funding from UCB Pharma to conduct this analysis. AE is an employee and shareholder of UCB Pharma. CF is an employee and shareholder of UCB Biopharma. UM is an employee and shareholder of UCB Pharma. MD declares competing interests from UCB (research grants received by his department and personal honorarium fees for participating at advisory boards), Novartis (research grants received by his department and personal honorarium fees for participating at advisory boards), Eli Lilly and Company (research grants received by his department and personal honorarium fees for participating at advisory boards), Pfizer (research grants received by his department and personal honorarium fees for participating at advisory boards), and AbbVie (research grants received by his department and personal honorarium fees for participating at advisory boards). VN-C is a speaker, consultant, and/or instructor for AbbVie, Eli Lilly and Company, Galapagos, Janssen, Moonlake, Novartis, Pfizer, and UCB Pharma; and has received grant and/or research support from AbbVie and Novartis. JAW declares competing interests from UCB, Novartis, Pfizer, Merck, AbbVie, Janssen, Amgen, and Sun Pharmaceutical.
